Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

STXS - Stereotaxis, Inc. So'nggi Yangiliklar | Finranks

Home

STXS

S

Stereotaxis, Inc. (STXS)

ASE – Real vaqt narxi. Valyuta: USD

1.82

-0.07 (-3.70%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

1.79

-0.03 (-1.49%)

Bozordan keyin: Mar 27, 2026, 5:44 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Stereotaxis: Medical Robotics Upside Offsets Cash Burn And Execution Risks

Stereotaxis: Medical Robotics Upside Offsets Cash Burn And Execution Risks

Stereotaxis targets early-stage endovascular robotics with differentiated magnetic navigation for electrophysiology and other minimally invasive procedures. Their MAGiC catheter recently received FDA approval, which I think strengthens STXS's razor-and-blade model by adding recurring disposable revenues. At this point, the bull case rests on STXS growing its early adoption into durable revenues across electrophysiology, endovascular, and connectivity applications.

Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript

Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript

Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript

Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates

Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.09 per share a year ago.

Stereotaxis Reports 2025 Full Year Financial Results

Stereotaxis Reports 2025 Full Year Financial Results

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m.

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany.

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC™ Magnetic Interventional Ablation Catheter. “FDA approval of MAGiC is a significant milestone for Stereotaxis and the community of physicians pioneering robotics in electrophysiology.

Videolar

No Data

There is no data to display

Press-relizlar

Stereotaxis Reports 2025 Full Year Financial Results

Stereotaxis Reports 2025 Full Year Financial Results

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany.

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC™ Magnetic Interventional Ablation Catheter. “FDA approval of MAGiC is a significant milestone for Stereotaxis and the community of physicians pioneering robotics in electrophysiology.

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference.